处方药物对HIV感染者抑郁症状和神经认知表现的影响
这项横断面研究在美国单中心纳入491名接受抑制性抗逆转录病毒治疗且血浆HIV RNA≤200拷贝/mL的HIV感染者,分析7项用药相关指标与抑郁症状及神经认知表现的关系。结果显示所有7项指标均与更差的整体神经认知表现相关,较高的抗胆碱能负荷及苯二氮䓬类、抗抑郁药使用与更多抑郁症状相关。作者认为苯二氮䓬类、阿片类和抗胆碱能药物与HIV感染者的认知和情绪障碍有关,可能时调整或减停药物可能有益。
要点
- 7项用药相关指标均与更差的整体神经认知表现相关(P<.0001至.0087)。
- 较高抗胆碱能负荷及苯二氮䓬类、抗抑郁药使用与更多抑郁症状相关。
- 苯二氮䓬类使用与所有认知域表现更差相关,阿片类与处理速度、运动功能、执行功能和工作记忆更差相关。
核心结论
- 苯二氮䓬类、阿片类和抗胆碱能药物的使用与HIV感染者的认知和情绪障碍有关。
- 作者认为,可能时调整或减停药物可能有益。
研究设计与样本
- 横断面研究,在美国单中心纳入491名HIV感染者。
- 所有参与者均接受抗逆转录病毒治疗且血浆HIV RNA≤200拷贝/mL。
- 分析7项用药相关指标(包括抗胆碱能负荷)与抑郁症状及神经认知表现的关系。
主要发现
- 参与者接受抗逆转录病毒治疗平均6.5年,多数(57.6%)CD4+ T细胞>500/µL。
- 全部7项用药相关指标均与更差的整体神经认知表现相关(P值<.0001至.0087)。
- 多变量模型证实较高的抗胆碱能负荷(P=.040)及苯二氮䓬类(P=.033)、抗抑郁药(P=.0011)使用和更多总用药数(P=.059)与更多抑郁症状相关(模型P<.0001)。
- 苯二氮䓬类(P=.0024)和阿片类(P=.043)使用及较高抗胆碱能负荷(P=.066)也与更差的神经认知表现相关。
- 苯二氮䓬类使用与所有认知域表现更差相关,阿片类使用与处理速度、运动功能、执行功能和工作记忆更差相关。
临床怎么用
- 作者认为,可能时调整或减停药物可能有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alterations in brain function and structure, such as depression and neurocognitive impairment, continue to occur in people with human immunodeficiency virus (HIV, PWH) taking suppressive antiretroviral therapy (ART). The lifespan of PWH has improved but the healthspan remains worse than people without HIV, in part because of aging-related diseases. As a result, polypharmacy is common and increases the risk of drug-drug interactions and adverse reactions. METHODS: This cross-sectional project investigated the relationship between 7 medication-related metrics (including anticholinergic burden), depressive symptoms, and neurocognitive performance in 491 PWH at a single center in the United States. All participants were taking ART and had plasma HIV RNA ≤ 200 copies/mL. RESULTS: Participants had taken ART for a mean of 6.5 years, and most (57.6%) had CD4+ T-cells >500/µL. All 7 medication-related metrics were associated with worse global neurocognitive performance (P value <.0001 to .0087). Multivariable models confirmed that higher anticholinergic burden (P = .040) and use of benzodiazepines (P = .033), antidepressants (P = .0011), and more total medications (P = .059) were associated with more depressive symptoms (model P < .0001). Use of benzodiazepines (P = .0024) and opiates (P = .043) along with higher anticholinergic burden (P = .066) were also associated with worse neurocognitive performance. Benzodiazepine use was associated with worse performance in all domains and opiate use was associated with worse performance in processing speed, motor function, executive function, and working memory. CONCLUSIONS: Use of benzodiazepines, opiates, and anticholinergic drugs contribute to cognitive and mood disorders in PWH. When possible, modifying or deprescribing medications may be beneficial.
引用
- Kamkwalala AR, Matthews A, Garg A, et al. The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV. Clin Infect Dis. 2025. PMID: 39658021. doi:10.1093/cid/ciae518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。